A new IHE report reveals a doubling of the number of cancerpatients in Ireland during the last 25 years. The direct costs of cancer have increased during this period to over €200 per capita, while the indirect costs have decreased to €120. Access to new cancer medicines is an area where Ireland is far away from the EU-15 average, as average reimbursement delays reach almost 2 years.